About
Science
Pipeline
Jobs
News
News
Read the latest from HI-Bio™
All
Press Releases
May 25, 2023
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy
Press Releases
April 18, 2023
HI-Bio Appoints Industry Veterans Uptal Patel, M.D., as Chief Medical Officer and Sunil Agarwal, M.D., as Board Member
Press Releases
April 11, 2023
HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy
News
April 11, 2023
Fierce Biotech: HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions
News
November 1, 2022
BioPharma Dive: Armed with $120M, HI-Bio joins race to develop better autoimmune disease drugs
News
November 1, 2022
Fierce Biotech: Arch-backed HI-Bio launches with 2 clinical-stage therapies from MorphoSys and $120M in cash
Press Releases
November 1, 2022
Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing
Press Releases
June 14, 2022
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
1
Contact Us
info@hibio.com